Highly Potent 17β-HSD2 Inhibitors with a Promising Pharmacokinetic Profile for Targeted Osteoporosis Therapy
- 27 November 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (23) , 10724-10738
Abstract
Intracellular elevation of E2 levels in bone by inhibition of 17β hydroxysteroid dehydrogenase type 2 (17β-HSD2) without affecting systemic E2 levels is an attractive approach for a targeted therapy against osteoporosis, a disease which is characterized by loss of bone mineral density. Previously identified inhibitor A shows high potency on human and mouse 17β-HSD2, but poor pharmacokinetic properties when applied perorally in mice. A combinatorial chemistry approach was utilized to synthesize truncated derivatives of A, leading to highly potent compounds with activities in the low nanomolar to picomolar range. Compound 33, comparable to A in terms of inhibitor potency against both human and mouse enzymes, displays high in vitro metabolic stability in human and mouse liver S9 fraction as well as low toxicity and moderate hepatic CYP inhibition. Thus, compound 33 showed a highly improved peroral pharmacokinetic profile in comparison to A, making 33 a promising candidate for further development.Keywords
Funding Information
- Bundesministerium f?r Bildung und Forschung (031A467)
This publication has 33 references indexed in Scilit:
- Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activitiesEuropean Journal of Medicinal Chemistry, 2014
- Ligand-Based Pharmacophore Modeling and Virtual Screening for the Discovery of Novel 17β-Hydroxysteroid Dehydrogenase 2 InhibitorsJournal of Medicinal Chemistry, 2014
- Sex Steroids and Bone Health Status in MenInternational Journal of Endocrinology, 2012
- 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17β-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidateBioorganic & Medicinal Chemistry Letters, 2006
- Inhibition of type 2 17β-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure–activity relationshipsSteroids, 2004
- Inhibitors of type II 17β-hydroxysteroid dehydrogenaseMolecular and Cellular Endocrinology, 2001
- Sex Steroids and BonePhysiological Reviews, 2001
- Spironolactone-related inhibitors of type II 17β-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activitiesBioorganic & Medicinal Chemistry, 1999
- 17β-Hydroxysteroid Dehydrogenases in Human Bone CellsJournal of Bone and Mineral Research, 1998
- A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and Contributes to Bone Loss in Aging MenJournal of Bone and Mineral Research, 1998